| Literature DB >> 27515369 |
Kaarel Krjutškov1,2,3, Mariann Koel2,4, Anne Mari Roost2, Shintaro Katayama1, Elisabet Einarsdottir1,3, Eeva-Mari Jouhilahti1, Cilla Söderhäll1,5, Ülle Jaakma2,6, Mario Plaas7, Liselotte Vesterlund1, Hannes Lohi3, Andres Salumets2,7,8,9, Juha Kere1,3.
Abstract
The transcriptome analysis of whole-blood RNA by sequencing holds promise for the identification and tracking of biomarkers; however, the high globin mRNA (gmRNA) content of erythrocytes hampers whole-blood and buffy coat analyses. We introduce a novel gmRNA locking assay (GlobinLock, GL) as a robust and simple gmRNA reduction tool to preserve RNA quality, save time and cost. GL consists of a pair of gmRNA-specific oligonucleotides in RNA initial denaturation buffer that is effective immediately after RNA denaturation and adds only ten minutes of incubation to the whole cDNA synthesis procedure when compared to non-blood RNA analysis. We show that GL is fully effective not only for human samples but also for mouse and rat, and so far incompletely studied cow, dog and zebrafish.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27515369 PMCID: PMC4981843 DOI: 10.1038/srep31584
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1The nature and reduction effect of GlobinLock.
(a) Schematic globin mRNA with possible masking oligonucleotides and anchored oligo-T primer. All oligo sequences and modifications are shown in Supplementary Table 1. (b) Five GL conditions and GL-negative controls were compared to measure globin α reduction fold change by qPCR. Template dilutions (10×) were used in this relative qPCR design and therefore the reduction effect up to ten is measured accurately according to existing dilution factor but fold change values above ten are out of the reported quantification range. (c) 3′-DNA long GL concentration effect on human globin α and β as measured by qPCR.
Figure 2The effective range and limitations.
(a) qPCR cycle threshold values are presented to indicate the number of required PCR cycles if less than 100 ng of whole-blood RNA is GL treated. (b) GL fold change reduction effect was measured by qPCR for three whole-blood RNA inputs: 1, 50 and 100 ng. (c) Scatter plot to measure the GL specificity based on an ERCC 92 mRNA spike-in mix over five different GL oligonucleotides compared with a GL-negative control. (d) The importance of the GL Tn tail for masking. Different GL oligonucleotides with variable lengths of Tn tails were analyzed, and the reduction effect of globin α was compared with the GL-negative experiment using qPCR.
Figure 3Reduction outcome.
(a) Human globin α and β mRNA reduction fold change based on the normalized prevalence over all genes detected in RNA-seq, with or without GL (red). (b) Venn diagram showing the total number of genes detected with or without GL treatment, where GL treatment revealed 1,178 unique genes when compared with the control. (c) Whole-blood RNA transcriptome normalized read count comparing five different GLs with a GL-negative control.